Breast Cancer
News
FDA Approves Pertuzumab for Metastatic HER2+ Breast Cancer
Conference Coverage
Paclitaxel Matches New Drugs as First-Line Breast Cancer Therapy
Major Finding: With a median follow-up of 12 months, progression-free survival was 10.6 months with paclitaxel, which was comparable to nab-...
Conference Coverage
Hodgkin's Survivors Face High Breast Cancer Risk
Major Finding: Nearly a third (30%) of females treated with chest radiation for Hodgkin’s lymphoma was diagnosed with breast cancer by age 50.Data...
Conference Coverage
T-DM1 Tops Capecitabine-Lapatinib in Advanced HER2-Positive Breast Cancer
Major Finding: Median progression-free survival was longer with T-DM1 than with capecitabine plus lapatinib (9.6 vs.
Conference Coverage
Docs Need Primer on Long-Term Effects of Chemotherapy
Major Finding: Only 6% of primary care physicians were able to identify the main long-term effects of doxorubicin, paclitaxel, oxaliplatin and...
News
Breast Brachytherapy Judged Superior in Tumor Bed Control
Major Finding: Tumor bed recurrence accounted for 28% of all recurrences after accelerated partial breast radiation vs. about 69% in previous...